Connect with us

Health

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Halts Its Decline

Published

on

In the last trading session, the stock price of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) gained 0.32% to close the day at $111.16. GW Pharmaceuticals is a biopharmaceutical company that concentrates its efforts on discovering, developing and commercializing innovative therapeutics from its proprietary CBD product platform in an extensive range of disease areas.

The highlights

As per a forecast report by Arcview Market Research, the development in the approved cannabis market will re-accelerate at the start of 2018, as adult use sales are anticipated to ramp up in Canada, Massachusetts and California along with medicinal sales in Florida. The market is anticipated to grow at a CAGR of 27% to $22.6 billion in 2021 from the $6.7 billion market value in the last year.

Polls demonstrate that 80% of Americans permit of legal access to medical cannabis while 60% approve of adult use legalization. That level of arrangement is rare on any policy concern and it’s allowing elected executives across the political spectrum to begin to move past the stigma previously linked with this issue. Hence, the companies in focus will be GW Pharmaceuticals, CANNABIS WHEATON I COM NPV (OTCMKTS:KWFLF), Axim Biotechnologies Inc (OTCMKTS:AXIM), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) and 22nd Century Group Inc (NYSEAMERICAN:XXII).

Forbes reported that retail sales in the United States from 20 jurisdictions came at $6.5 billion, however as per Greenwave Advisors, that figure is estimated to grow to $30 billion by 2021. In attempt to meet the demand for consumers, the makers and growers of infused offerings have to scale up their businesses. More square footage, more automation and the ability to accomplish this fast growth are separating the pop and mom shops from corporate cannabis.

GW Pharmaceuticals is advancing an orphan drug plan in the segment of childhood-onset epilepsy with a concentration on Epidiolex®, which is in Phase III clinical advancement for the cure of Dravet syndrome, Tuberous Sclerosis Complex, Infantile Spasms and Lennox-Gastaut syndrome.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement